Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Alex Eustace

Has grant

Assistant Professor in Biotechnology

Dublin City University

Ireland

Research Interests

Explore related searches

Professors in Ireland Professors in Immunology Immunology professors in Ireland

About

Alex Eustace is an Assistant Professor in Biotechnology at Dublin City University, Ireland. His research focuses on precision oncology, cancer therapeutics, and biomarker analysis, particularly in the context of breast cancer. Recent publications highlight his work on neoadjuvant therapy responses, immune cell alterations, and innovative biomedical applications of carbon dots. He actively contributes to the translation of basic scientific discoveries into clinical practice.

Recent Grants

Grant: Close

Developing a personalised medicine approach for ERBB-mutant breast cancer

Open Date: 2017-03-01

Close Date: 2020-02-01

Grant: Close

ERBB-family mutations as sensitivity biomarkers for the PI3K inhibitor copanlisib

Open Date: 2015-03-01

Close Date: 2016-02-01

Grant: Close

Novel Kinome Aberrations in HER2-Positive Breast Cancer Therapy Resistance

Open Date: 2013-09-01

Close Date: 2014-09-01

Grant: Close

Novel Kinome abberations in HER2-positive Breast cancer therapy resistance

Open Date: 2012-09-01

Close Date: 2015-08-01

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (18)

Cathy Richards

Lecturer

Royal College of Surgeons in Ireland

IRELAND

Alex Eustace

Research Interests

Explore related searches

About

Recent Grants

Articles (17)

TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

TP53 Mutation-Specific Dysregulation of Store-Operated Calcium Entry and Apoptotic Sensitivity in Triple-Negative Breast Cancer

Translating Basic Science Discoveries into Clinical Advances: Highlights from the EACR-AACR-IACR 2024 Conference in Celebration of Irish Association for Cancer Research’s 60th Anniversary

Synthesis of carbon dots from spent coffee grounds: transforming waste into potential biomedical tools.

Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference

CARBON DOTS: Bioimaging and Anticancer Drug Delivery

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.

Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer

Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Collaborators (18)

Cathy Richards

Kellie Dean

Paul J. Buchanan

Sandra Roche

Silvia Giordani

Seodhna Lynch

Sinead Toomey

John Crown

Dirk Fey

Niamh Buckley

Arman Rahman

Denis Collins

Walter Kolch

Daniela Iacopino

Simon Furney

Simone Marcone

Eric Fey

Kathy Gately

Make your next move.